timothy sykes logo

Stock News

Citi Initiates Buy Coverage on Rhythm Pharmaceuticals with Price Target Set for Growth

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 12/11/2025, 11:33 am ET 12/11/2025, 11:33 am ET | 4 min 4 min read
Citi Initiates Buy Coverage on Rhythm Pharmaceuticals with Price Target Set for Growth Thumbnail

Rhythm Pharmaceuticals Inc.’s stocks have been trading up by 14.09 percent, driven by promising news in market developments.

Candlestick Chart

Live Update At 11:32:54 EST: On Thursday, December 11, 2025 Rhythm Pharmaceuticals Inc. stock [NASDAQ: RYTM] is trending up by 14.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

When we talk about money, Rhythm Pharmaceuticals has numbers that show where they stand. They reported a revenue of $130.13M, with each share bringing in about $1.95. But, not all numbers are happy. The company faces challenges like a high operating expense reaching $98.45M which surpasses the revenue.

From the looks of it, their cost to bring in money is pretty high, weighing down on their ability to make a profit. Their overall expenses and spending are more than the money they bring in, causing a net loss standing at $52.9M.

Stocks, on the other hand, show mixed signs. Recently, their closing prices have seen an upward trend, reaching as high as $119.84 from a low of $100 previously. This growth suggests there is positive sentiment in the market, possibly influenced by recent developments in their FDA dealings and upcoming research results. But remember, prices can change very quickly based on news and market feel, so it’s very important to keep an ear to the ground!

Market Reactions

In terms of the market itself, the predictions of Citi pointing towards a possible FDA nod for Imcivree appear like a green light for investors. This has steered the stock steadily uphill, inviting interest from those looking to bet on promising biotech ventures.

However, it can’t be ignored that Rhythm Pharmaceuticals operates in a complex market with high spending and yet-to-be-realized revenues from innovations. Their position in the market shows stringent management of finances is needed. The ongoing trials may require additional investments in time and resources. Investors are advised to watch for shifts in their operational strategy and financial practices, as the company’s moving parts are only as strong as their ability to perform swiftly under changing tides.

In light of recent news, potential positive trial results indicate a boon for stock prices, but with a float of pending FDA approval, patient investors might reap benefits if predictions steer the course correctly. The unfolding outcome of Citigroup’s superior price target could pave the way for a robust setting where past pitfalls in pricing could possibly dissipate.

More Breaking News

Conclusion

Looking inside Rhythm Pharmaceuticals shows an intricate dance of challenges and potential victories. At the heart of the matter lays promising research and upcoming drug developments, providing hope for both the company and its supporters. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This wisdom resonates with the ongoing journey of Rhythm Pharmaceuticals. While their steps towards further FDA acknowledgments in treating rare neuroendocrine diseases add glitter to their market position, sustaining a climb in stock value revolves around securing successful trial outcomes and refining their expense structure. The recent moves and upbeat projections mark a possible positive trajectory, albeit cautious ones, in the still-unfolding narrative of Rhythm Pharmaceuticals—a tale of aligning strategic actions with market expectations and recognizing that the road to success is paved with continual learning and adaptation.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”